Redefining how medicines are made.

Amir Nashat, ScD

Chief Executive Officer

Amir is the CEO of Soufflé Therapeutics where his focus on designing potent, precise, and safe medicines for patients drives our mission.

Amir remains an Entrepreneur Partner at Polaris Partners today, where he previously served as Managing Partner.  While at Polaris, Amir worked with groundbreaking companies such as Alnylam Pharmaceuticals and Acceleron Pharma, and led investments in/founded: Dewpoint Therapeutics, Fate Therapeutics, Jnana Pharmaceuticals, Living Proof, Morphic Therapeutics, Paratus Sciences, Receptos Pharmaceuticals, and Scholar Rock.  He currently serves as a director of Camp4 (NASDAQ: CAMP), Dewpoint, Matter Neuroscience and Paratus.

Amir serves on the investment committee of Partners Innovation Fund and is a member of the Innovation Advisory Board of Mass General Brigham. Amir helped to launch the MIT Sandbox Innovation Fund as its President.

Prior to his career at Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at MIT with a minor in Biology, and worked in the lab of Dr. Robert Langer. Amir earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Susan Langer

Chief Business Officer

Susan is Chief Business Officer and Founding President of Soufflé Therapeutics. Susan brings extensive expertise in company building, corporate strategy and business development to Soufflé.

Before Soufflé, Susan was President or on the founding management team for several biotech start-ups including Paratus Sciences. Prior to that, Susan held roles of increasing responsibility at Biogen across different therapeutic areas including as the Head of Corporate Strategy. Susan currently serves on the Board of Directors of Biogen.

In addition to her roles in biotech strategy and leadership, Susan has served as Venture Partner at Old Silver VC and Managing Partner at Guava Partners. Susan obtained her bachelor’s degree from the College of Arts and Sciences at Cornell University.

Vadim Dudkin, PhD

Founding Chief Technology Officer

As the Founding Chief Technology Officer, at Soufflé Therapeutics, Vadim leads research, discovery and development to translate breakthroughs into medicines for patients.

Bringing more than 20 years of experience, Vadim has led multiple platform and biology teams focusing on nucleic acids, small molecules, and radiopharmaceuticals which have contributed to numerous development and clinical candidates. He previously served as Founder and Global Head of RNA and Targeted Therapeutics at Johnson and Johnson (J&J), with worldwide platform responsibility for RNA medicines, protein conjugates, ADCs and the targeted nanotherapies discovery portfolio. Prior to this, Vadim led an internal venture research team at J&J that established a universal protein targeting platform, contributing to the creation of Poseida, Fusion, and Aro Biotherapeutics. Vadim began his career at Merck, where he held roles of increasing responsibility, eventually leading a team focused on siRNA conjugate research.

Vadim earned his PhD from University of Illinois and completed his postdoctoral training at Memorial Sloan Kettering Cancer Center.

Roman Bogorad, PhD

SVP, Discovery Biology

Roman joined Soufflé Therapeutics in 2021 as the Founding Head of Discovery Biology, bringing deep expertise in nucleic acid-based therapeutics and a strong track record across both industry and academia.

Prior to Soufflé, he held roles of increasing responsibilities at several biotechnology companies, including Senda Biosciences (now Sail Biomedicine), where he led R&D in extrahepatic delivery for gene editing and gene therapy applications. At CRISPR Therapeutics, Roman led in vivo liver-focused preclinical editing programs.

Before transitioning to industry, Roman was a research scientist at the Massachusetts Institute of Technology in the labs of Professors Robert Langer and Daniel Anderson. He earned his PhD from Moscow State University and completed his postdoctoral training at Université Paris V in Paris, France. Roman is the author of over 40 peer-reviewed publications in journals such as Nature, Nature Biotech, PNAS, and is an inventor on multiple granted patents and pending applications.

Lorenzo Benatuil, PhD

VP, Protein Science

Lorenzo serves as VP, Head of Protein Science at Soufflé Therapeutics. He is a drug discovery leader with 17 years of experience advancing therapeutics to clinical development. His work has contributed to eight drug candidates in clinical trials across oncology, immunology, and age-related diseases. Lorenzo is an inventor on 22 U.S. patents and has served as a scientific advisor to the WHO’s International Nonproprietary Names group.

At Soufflé, Lorenzo leads internal and external teams in antibody discovery, conjugation development, and optimization of our lead therapeutics. Prior to joining Soufflé, Lorenzo served as Executive Director at Dragonfly Therapeutics developing novel NK cell–engaging therapies. Previously, he spent over a decade at AbbVie, advancing multiple therapeutic programs, rising to senior leadership, heading the Biologics group for the AbbVie–Calico collaboration, and earning recognition as an AbbVie Research Fellow. Lorenzo earned his PhD in Immunology and completed postdoctoral training at Harvard Medical School.

He is passionate about translating science into medicines that help patients while inspiring the next generation of scientific leaders.

Srividya Subramanian, PhD, JD

SVP, General Counsel

Srividya (Vidya) joined Soufflé Therapeutics in 2024 and brings over 17 years of expertise advising numerous biotechnology companies, in both in-house and external legal roles.

Prior to Soufflé, Vidya was most recently VP, Deputy General Counsel at Ikena Oncology, leading the legal and intellectual property functions and helped drive multiple financing and strategic transactions. Vidya also led the intellectual property strategy at Compass Therapeutics. Prior to moving in-house, Vidya was at Nixon Peabody, LLP, for over 10 years where she advised biotech companies and academic institutions on intellectual property and business development, across a wide range of modalities and therapeutic areas.

Vidya received her Juris Doctorate degree from Suffolk University Law School, magna cum laude, with a concentration in Intellectual Property, and her PhD in Immunology from The University of Texas, Southwestern Medical Center. She completed her research fellowship training at Boston Children’s Hospital. She is admitted in the Commonwealth of Massachusetts and with the U.S. Patent and Trademark Office. Vidya currently serves on the Board of Directors of Service Stars, a Massachusetts non-profit organization.

Mark Angelino, PhD

Chief Strategy & Operating Officer

Mark joined Soufflé Therapeutics in 2023 as Chief Strategy & Operating Officer where he brings extensive expertise in both strategic execution and operational oversight across the biotech ecosystem.

Prior to Soufflé, Mark was a Venture Partner at Third Rock Ventures with a focus on novel approaches in genetic medicines. Prior to that, Mark co-founded and served as Chief Operating Officer at Generation Bio, an organization focused on development of non-viral, genetic medicines. Previously, Mark was on the formative leadership team at Bluebird Bio, where he held roles as Head of Pharmaceutical Sciences and Rare Disease Franchise Lead helping to pioneer the early gene therapy scientific, regulatory, and commercial landscape.

In his earlier career, Mark held various roles in R&D and operations across a number of therapeutic modalities at companies like Baxter Healthcare, Archemix, Momenta, Millennium and DuPont Pharma. Mark has spent the majority of his career focused on translating novel modalities into therapeutics that can improve patients’ lives, resulting in the development of seven approved medicines.

Rebecca Stevenson

Chief Financial Officer

Becky serves as Chief Financial Officer at Soufflé Therapeutics where she leads capital formation, investor relations, and financial operations.

Becky joined Soufflé after an almost 20-year career in Banking where she was recognized for her effective leadership in corporate and financial strategy and operational execution, as well as her ability to lead and scale teams of varying sizes and expertise within the U.S. and globally. In her most recent role at HSBC, Becky built and ran the firm's Healthcare Investment Banking franchise for the Americas. Earlier in her career, she spent 15 years in roles of increasing responsibility at Wells Fargo where she built and ran the firm's early-stage Life Sciences efforts including establishing their first VC/Institutional Investor coverage.

Becky has advised both early-stage and large corporate Life Sciences organizations on long-term financing strategies to enable their scientific and clinical progress, including private capital raises, IPOs, Follow-ons, At-the-Market-Offerings, convertible and corporate bonds, as well as M&A, business development and licensing strategies.

Becky’s applies her financial expertise in the service of patients and is a long-standing board member of the American Cancer Society of New England.

Ellen Rohde, PhD

VP, Preclinical Development

Ellen is VP, and Head of Preclinical Development at Soufflé Therapeutics. In her role she provides pharmacological insights, enables bioanalytical capabilities, executes toxicological studies and pursues translational and quantitative medicine approaches to characterize novel genetic medicines.

Prior to Soufflé she pioneered the understanding of PK/PD and biodistribution of LNP-delivered gene editing medicines at Verve Therapeutics and Intellia Therapeutics. She led teams that successfully advanced five Cas9 or base editors into clinical trials.

Ellen held roles of increasing responsibility at Biogen and Merck where she built extensive expertise in drug development, bioanalysis, drug disposition, non-viral drug delivery and translational sciences. Ellen is a strong leader, having led teams of up to 30 scientists with in vivo pharmacology, bioanalytical, QSP modeling, toxicology and biomarker expertise.

Ellen has authored or contributed to more than 30 scientific publications, reflecting her significant impact on advances in drug development. She received her PhD in Analytial Chemistry from the University of Cincinnati and her diploma in Physical and Theoretical Chemistry from the University of Leipzig, Germany. She went on to conduct postdoctoral studies in biological mass spectrometry and proteomics at the Mayo Clinic and Abbott Laboratories.

Ni Sun

VP, Regulatory

Ni is VP, Head of Regulatory Affairs at Soufflé Therapeutics. With over 15 years of experience in drug development, she brings extensive expertise across multiple disease areas and therapeutic modalities. Her career is marked by roles of increasing responsibility, where she led global regulatory strategy for innovative therapies across multiple indications.

At CRISPR Therapeutics, she contributed to the development of CAR-T therapies for oncology, autoimmune disorders and in vivo lipid nanoparticle (LNP) platforms for cardiovascular disease. Prior to that, she led regulatory efforts for RNA therapies for Duchenne muscular dystrophy at Sarepta Therapeutics, and held earlier regulatory roles at Fresenius Medical Care, Alkermes and Pfizer. Through these roles, Ni has contributed to new drug approvals including VIVITROL® (naltrexone), ARISTADA® (aripiprazole lauroxil) and VELPHORO® (sucroferric oxyhydroxide).

Ni holds a BS degree in biological sciences from Nanjing University and a MS degree in nutritional science from The Ohio State University.

Victoria Bartlett, PhD

VP, Program and Alliance Management

Victoria is VP, Head of Program and Alliance Management at Soufflé Therapeutics, bringing over 25 years of biopharmaceutical experience in program, alliance, and portfolio management. Previously, Victoria built the program management function at Verve Therapeutics, supporting gene editing programs and strategic partnerships.

Prior to that Victoria served as Senior Director at Akcea, overseeing Phase 2 clinical programs for three antisense oligonucleotides: pelacarsen, vupanorsen, and TRYNGOLZA™ (olezarsen). Following Ionis Pharmaceuticals’ acquisition of Akcea Therapeutics, Victoria joined their organization to manage cardio-renal partnerships.

Earlier in her career, Victoria spent six years as a bench scientist at Paratek Pharmaceuticals before transitioning to leadership roles at Wyeth Research/Pfizer, Moderna, and CRISPR Therapeutics. She holds a BS degree and PhD in Pharmacology from the University of Liverpool and completed a four-year postdoctoral fellowship at Harvard Medical School.

Herb Stevenson, MD

VP, Clinical Development

Herb is VP, Head of Clinical Development at Soufflé Therapeutics. He brings over 26 years of experience in drug development and academic medicine to Soufflé Therapeutics, with a focus on delivering transformative therapies to patients with unmet needs. His expertise spans multiple disease areas and therapeutic modalities.

Prior to joining Soufflé, Herb served as Senior Director of Clinical Development at Sarepta Therapeutics. During his tenure, he led eight distinct genetic therapy programs, including AAV and oligonucleotide therapies, ranging from pre-IND through global Phase 3 and Phase 4 studies. He played a pivotal role in multiple successful IND filings, first-in-human clinical trials, and the successful BLA approval of AMONDYS 45® (casimersen).

Herb received his medical degree from the University of Vermont College of Medicine. A recognized expert in his field, he has served in multiple medical leadership roles, lectured nationally and internationally, and authored over 40 peer-reviewed publications in journals such as Nature Medicine.

Victor Kotelianski, MD, PhD, ScD

Victor is an internationally recognized scientist and pioneer in genetic medicine with more than 25 years’ experience in the biotech industry. Victor was founding Senior Vice President of Research and Distinguished Fellow at Alnylam where he led preclinical pipeline development. He co-invented Inclisiran, helped to develop the TTR franchise, and shaped the foundation of the siRNA platform. Victor was also the first Distinguished Investigator at Biogen and a member of their research management team. At both Alnylam and Biogen, Victor led numerous collaborations with academic institutions and pharmaceutical companies.

Victor is co-author of more than 250 publications in leading international journals and inventor of more than 40 patents. Victor was Founding Director of the Center of RNAi Therapeutics and Functional Genomics (MIT-Skoltech) in Moscow. He served as visiting fellow at the Koch Institute of Integrative Cancer Research at Massachusetts Institute of Technology (MIT). Victor was Director of INSERM at the Institut Curie in Paris and Professor of Cell and Molecular Biology at the National Cardiology Research Center in Moscow.

Victor received a PhD in Molecular Biology from the Institute of Protein Research, USSR National Academy of Science. He also holds a MD from Uzhgorod University Medical School and a ScD from National Cardiology Research Center, Academy of Medical Sciences in Moscow.

Daniel Anderson, PhD

Daniel G. Anderson is the Joseph R. Mares (1924) Professor of Chemical Engineering, a core member of the Institute for Medical Engineering and Science, and an intramural member of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). He is a leading researcher in the fields of nanotherapeutics and biomaterials. His work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science, and has resulted in the publication of more than 500 papers, patents, and patent applications. He has founded several companies, including Living Proof, Olivo Labs, CRISPR Therapeutics, Sigilon Therapeutics, Verseau Therapeutics, oRNA, VasoRx, and Soufflé Therapeutics. He is a member of National Academy of Medicine, the Harvard-MIT Division of Health Science and Technology, a fellow of the National Academy of Inventors, and is an affiliate of the Broad and Ragon Institutes.

Robert Langer, ScD

Dr. Bob Langer is one of nine Institute Professors at Massachusetts Institute of Technology (MIT), MIT’s highest faculty honor. His pioneering work has benefited billions worldwide. Langer has authored over 1,600 papers, cited more than 459,000 times. With an h-index of 331, Langer is the most cited engineer in history. His patents have been licensed or sublicensed to over 400 companies, and he has co-founded more than 40 ventures. Langer chaired the FDA’s Science Board from 1999–2002 and has received over 220 awards, including the U.S. National Medal of Science and the National Medal of Technology and Innovation (one of only three living individuals to receive both), the Draper Prize (considered engineering’s Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize in Chemistry, Millennium Technology Prize, and the Kavli Prize in Nanoscience. He holds 45 honorary doctorates from institutions such as Harvard, Yale, Columbia, and Oxford, and has been elected to the National Academies of Medicine, Engineering, and Sciences, as well as the National Academy of Inventors.

Marino Zerial, PhD

Prof. Marino Zerial is the Director of Human Technopole (HT), Italy's premier national research institute for the life sciences, a position he has held since 2023. At the Institute, Prof. Zerial is responsible for setting the scientific vision and providing leadership to a team of world class scientists focused on high-impact basic and translational research integrating experimental and computational sciences to study biological processes relevant for human diseases. At Human Technopole, Prof. Zerial also leads a research group focusing on the role of endocytosis in the delivery of macromolecular therapeutics, as well as the molecular and cellular mechanisms underlying liver diseases.

Prior to his appointment at HT, Prof. Zerial spent over two decades as a cornerstone of the German scientific community. In 1998, he co-founded and became Director of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden. There, Prof. Zerial made seminal contributions to the understanding of the molecular mechanisms of intracellular trafficking focusing on the mechanistic dissection of Rab GTPases in organelle biogenesis and membrane fusion. During this period, he also held an Honorary Professorship at the Faculty of Medicine, Technische Universität of Dresden. Prof. Zerial is a distinguished contributor to scientific literature having co-authored over 220 publications including in preeminent journals such as Nature, Science and Cell.

Prof.  Zerial’s earlier career was shaped at the European Molecular Biology Laboratory (EMBL) in Heidelberg, where he served as Research Group Leader from 1989. This followed extensive postdoctoral research at the Institut Jacques Monod in Paris and at EMBL and a BSc in Biology from the University of Trieste.

Brad Pentelute, PhD

Bradley L. Pentelute is Professor of Chemistry at Massachusetts Institute of Technology (MIT), an Associate Member of the Broad Institute of Harvard and MIT, an Extramural Member of the MIT Koch Institute for Integrative Cancer Research, and a Member of the Center for Environmental Health Sciences at MIT.

Brad is a globally recognized leader in the development of new chemistry to help deliver molecules in to cells and improve the efficacy potential of new medicines. His work has formed the foundation for new therapeutic approaches and enabled multiple novel medicines currently in clinical development. Brad has co-authored more than 150 publications including in preeminent journals such as Nature and Science and is an inventor on more than 30 patents. He has founded several biotech organizations including Amide Technologies, Resolute Bio, Tegrigen Therapeutics, New Frontier Bio, Decoy Therapeutics, Darbix and Abiologics.

In academia, Brad is a leader in nurturing the next generation of chemists, having supervised over 100 scientists to date through their PhDs and post-doctoral research at MIT. He earned his undergraduate degrees in Psychology and Chemistry from the University of Southern California, followed by an MS and PhD in Organic Chemistry from the University of Chicago. He completed postdoctoral training in Microbiology at Harvard Medical School.